Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogenic driver in NSCLC. There seems to be a differential...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Zhu, Viola W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474217/
https://www.ncbi.nlm.nih.gov/pubmed/34589933
http://dx.doi.org/10.1016/j.jtocrr.2020.100037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474217/
https://www.ncbi.nlm.nih.gov/pubmed/34589933
http://dx.doi.org/10.1016/j.jtocrr.2020.100037

Ejemplares similares